MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/120/0.1/20.09.24

MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/120/0.1/20.09.24 Share Price

DE000ME1CEX7

Market Closed - Börse Stuttgart 10:12:22 31/05/2024 pm IST
0.015 ^EUR	-.--%

1 month	-11.76%
3 months	-55.88%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/120/0.1/20.09.24

Latest news about GILEAD SCIENCES, INC.

Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival	31/05	RE
Gilead Sciences Says Phase 3 Study Shows Trodelvy Cut Risk of Death by 16% in Non-Small Cell Lung Cancer Patients	31/05	MT
Disaster averted	31/05
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024	31/05	BU

More news

Quotes 5-day view

Date	Price	Change
31/24/31	0.015	-.--%
30/24/30	0.015	-.--%
29/24/29	0.015	+15.38%
28/24/28	0.013	-.--%
27/24/27	0.013	-18.75%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 10:12 pm IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Morgan Stanley
WKN	ME1CEX
ISIN	DE000ME1CEX7
Date issued	29/09/2023
Strike	120 $
Maturity	20/09/2024 (111 Days)
Parity	10 : 1
Emission price	0.08 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.09 €
Lowest since issue	0.007 €
Spread	0.025 €
Spread %	62.50%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Gilead Sciences, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

64.27 USD

Average target price

82.7 USD

Spread / Average Target

+28.67%

Consensus